Economic and disease burden of RSV-associated hospitalizations in young children in France, from 2010 through 2018

C Demont, N Petrica, I Bardoulat, S Duret, L Watier, A Chosidow, M Lorrot, A Kieffer, M Lemaitre, C Demont, N Petrica, I Bardoulat, S Duret, L Watier, A Chosidow, M Lorrot, A Kieffer, M Lemaitre

Abstract

Background: Respiratory syncytial virus (RSV) is the main cause of infant and child hospitalizations. The study objective is to estimate the RSV-associated hospitalizations and economic burden in young children in France to inform future preventive strategies.

Methods: We conducted a retrospective analysis of RSV-associated hospitalizations data from the French Hospital database (PMSI-MCO) which covers the entire French population. All children aged < 5 years hospitalized with RSV ICD-10 codes (J210, J219, J45, J121, J205, R062) from 2010 to 2018, were included. Descriptive analyses were conducted by RSV seasons (Oct to March), by respiratory years (July to June) and per age groups.

Results: On average 45,225 RSV-associated hospitalizations (range: 43,715 - 54,616) per season was reported in France, 69% among children < 1 year old. This represents 28% of all-cause hospitalizations that occurred among children < 1 year old, and less than 10% of all-cause hospitalizations in older children. Number of RSV-associated hospitalizations were similar for infants born during (Oct-March) or outside (April-September) their first RSV season. The highest risk being reported for infants born from September through November. The associated hospitalization cost increased between 2010 - 11 and 2017-18, from €93.2 million to €124.1 million, respectively, and infants < 1 year old represented 80% of the economic burden.

Conclusion: RSV is an important cause of child hospitalization in France. The burden on healthcare system is mainly driven by < 1 year olds, and preventive strategies should be implemented before the first RSV season.

Keywords: Burden; Children; Hospitalization; Respiratory syncytial virus; Socio-economic impact.

Conflict of interest statement

NP, SD, Magali Lemaitre and IB are employees of IQVIA. AK and CD are Sanofi employees and may hold shares and/or stock options in the company. AC, Mathie Lorrot and LW had received consulting fees from IQVIA for the study.

© 2021. The Author(s).

Figures

Fig. 1
Fig. 1
Rate of RSV-associated hospitalizations, per 1000 person-month, by RSV season and age group, from 2010 through 2018 in France
Fig. 2
Fig. 2
Impact of the month of birth on the risk of RSV-associated hospitalization (RSV-specific ICD-10 codes) from 2010 through 2018 in France
Fig. 3
Fig. 3
RSV associated hospitalization cost distribution by age group during RSV seasons from 2010 through 2018 in France

References

    1. Shi T, McAllister DA, O’Brien KL, Simoes EAF, Madhi SA, Gessner BD, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. Lancet. 2017;390(10098):946–958. doi: 10.1016/S0140-6736(17)30938-8.
    1. Paes BA, Mitchell I, Banerji A, Lanctôt KL, Langley JM. A decade of respiratory syncytial virus epidemiology and prophylaxis: translating evidence into everyday clinical practice. Can Respir J. 2011;18(2):e10–e19. doi: 10.1155/2011/493056.
    1. Bont L, Checchia PA, Fauroux B, Figueras-Aloy J, Manzoni P, Paes B, Simões EAF, Carbonell-Estrany X. Defining the epidemiology and burden of severe respiratory syncytial virus infection among infants and children in Western countries. Infect Dis Ther. 2016;5(3):271–298. doi: 10.1007/s40121-016-0123-0.
    1. Blanken MO, Rovers MM, Molenaar JM, Winkler-Seinstra PL, Meijer A, Kimpen JLL, Bont L. Respiratory syncytial virus and recurrent wheeze in healthy preterm infants. N Engl J Med. 2013;368(19):1791–1799. doi: 10.1056/NEJMoa1211917.
    1. Hall CB, Weinberg GA, Iwane MK, Blumkin AK, Edwards KM, Staat MA, Auinger P, Griffin MR, Poehling KA, Erdman D, Grijalva CG, Zhu Y, Szilagyi P. The burden of respiratory syncytial virus infection in young children. N Engl J Med. 2009;360(6):588–598. doi: 10.1056/NEJMoa0804877.
    1. Barr R, Green CA, Sande CJ, Drysdale SB. Respiratory syncytial virus: diagnosis, prevention and management. Therapeutic Advances in Infection. 2019;6:204993611986579. doi: 10.1177/2049936119865798.
    1. Haute Autorite de Sante. Synagis - Comission de la transparence, 5 avril 2017 [Internet]. [cited 2020 Apr 22]. Available from: . Accessed 22 Apr 2020.
    1. Obando-Pacheco P, Justicia-Grande AJ, Rivero-Calle I, Rodríguez-Tenreiro C, Sly P, Ramilo O, Mejías A, Baraldi E, Papadopoulos NG, Nair H, Nunes MC, Kragten-Tabatabaie L, Heikkinen T, Greenough A, Stein RT, Manzoni P, Bont L, Martinón-Torres F. Respiratory syncytial virus seasonality: a global overview. J Infect Dis. 2018;217(9):1356–1364. doi: 10.1093/infdis/jiy056.
    1. Grimprel E, Francois P, Olivier C, Fortier G, Thevenieau D, Pautard JC, Boulesteix J, Delmas P, Marguet C. Epidémiologie clinique et virologique de la bronchiolite du nourrisson. Enquête nationale multicentrique (I) Med Mal Infect. 1993;23:844–850. doi: 10.1016/S0399-077X(05)80361-0.
    1. Che D, Nicolau J, Bergounioux J, Perez T, Bitar D. Bronchiolite aiguë du nourrisson en France : bilan des cas hospitalisés en 2009 et facteurs de létalité. Arch Pediatr. 2012;19(7):700–706. doi: 10.1016/j.arcped.2012.04.015.
    1. Kramer R, Duclos A, Lina B, Casalegno J-S. Cost and burden of RSV related hospitalisation from 2012 to 2017 in the first year of life in Lyon. France Vaccine. 2018;36(45):6591–6593. doi: 10.1016/j.vaccine.2018.09.029.
    1. McLaurin KK, Farr AM, Wade SW, Diakun DR, Stewart DL. Respiratory syncytial virus hospitalization outcomes and costs of full-term and preterm infants. J Perinatol. 2016;36(11):990–996. doi: 10.1038/jp.2016.113.
    1. Bezin J, Duong M, Lassalle R, Droz C, Pariente A, Blin P, Moore N. The national healthcare system claims databases in France, SNIIRAM and EGB: powerful tools for pharmacoepidemiology. Pharmacoepidemiol Drug Saf. 2017;26(8):954–962. doi: 10.1002/pds.4233.
    1. Boudemaghe T, Belhadj I. Data resource profile: the french national uniform hospital discharge data set database (PMSI) Int J Epidemiol. 2017;46(2):392–392d. doi: 10.1093/ije/dyw359.
    1. CNIL. Méthodologie de référence MR-006 - Études nécessitant l’accès aux données du PMSI par les industriels de santé [Internet]. [cited 2020 Sep 22]. Available from: . Accessed 3 Sept 2020.
    1. Institut national de la statistique et des études économiques (INSEE). Evolution et structure de la population [Internet]. [Population structure and its evolution]. 2020. Available from: . Accessed 17 June 2020.
    1. Cai W, Tolksdorf K, Hirve S, Schuler E, Zhang W, Haas W, Buda S. Evaluation of using ICD-10 code data for respiratory syncytial virus surveillance. Influenza Other Respir Viruses. 2020;14(6):630–637. doi: 10.1111/irv.12665.
    1. Green CA, Yeates D, Goldacre A, Sande C, Parslow RC, McShane P, Pollard AJ, Goldacre MJ. Admission to hospital for bronchiolitis in England: trends over five decades, geographical variation and association with perinatal characteristics and subsequent asthma. Arch Dis Child. 2016;101(2):140–146. doi: 10.1136/archdischild-2015-308723.
    1. Reeves RM, Hardelid P, Gilbert R, Warburton F, Ellis J, Pebody RG. Estimating the burden of respiratory syncytial virus (RSV) on respiratory hospital admissions in children less than five years of age in England, 2007-2012. Influenza Other Respir Viruses. 2017;11(2):122–129. doi: 10.1111/irv.12443.
    1. Gill PJ, Goldacre MJ, Mant D, Heneghan C, Thomson A, Seagroatt V, Harnden A. Increase in emergency admissions to hospital for children aged under 15 in England, 1999-2010: national database analysis. Arch Dis Child. 2013;98(5):328–334. doi: 10.1136/archdischild-2012-302383.
    1. Naouri D, El Khoury C, Vincent-Cassy C, Vuagnat A, Schmidt J, Yordanov Y, et al. The French emergency national survey: a description of emergency departments and patients in France. Bouchama A, editor. PLoS One. 2018;13(6):e0198474. 10.1371/journal.pone.0198474.
    1. Ségala C, Poizeau D, Mesbah M, Willems S, Maidenberg M. Winter air pollution and infant bronchiolitis in Paris. Environ Res. 2008;106(1):96–100. doi: 10.1016/j.envres.2007.05.003.
    1. Jepsen MT, Trebbien R, Emborg HD, Krause TG, Schønning K, Voldstedlund M, et al. Incidence and seasonality of respiratory syncytial virus hospitalisations in young children in Denmark, 2010 to 2015. Euro Surveill. 2018;23(3):17-00163.
    1. Lloyd PC, May L, Hoffman D, Riegelman R, Simonsen L. The effect of birth month on the risk of respiratory syncytial virus hospitalization in the first year of life in the United States. Pediatr Infect Dis J. 2014;33(6):e135–e140. doi: 10.1097/INF.0000000000000250.
    1. Ogilvie MM, Santhire Vathenen A, Radford M, Codd J, Key S. Maternal antibody and respiratory syncytial virus infection in infancy. J Med Virol. 1981;7(4):263–271. doi: 10.1002/jmv.1890070403.
    1. Glezen WP, Paredes A, Allison JE, Taber LH, Frank AL. Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group, and maternal antibody level. J Pediatr. 1981;98(5):708–715. doi: 10.1016/S0022-3476(81)80829-3.
    1. Reeves RM, Hardelid P, Panagiotopoulos N, Minaji M, Warburton F, Pebody R. Burden of hospital admissions caused by respiratory syncytial virus (RSV) in infants in England: a data linkage modelling study. J Infect. 2019;78(6):468–475. doi: 10.1016/j.jinf.2019.02.012.
    1. Janet S, Broad J, Snape MD. Respiratory syncytial virus seasonality and its implications on prevention strategies. Hum Vaccin Immunother. 2017;14(1):234–244. doi: 10.1080/21645515.2017.1403707.
    1. Chirikov VV, Simões EAF, Kuznik A, Kwon Y, Botteman M. Economic-burden trajectories in commercially insured US infants with respiratory syncytial virus infection. 2020;221(8):1244-55.
    1. Cromer D, van Hoek AJ, Jit M, Edmunds WJ, Fleming D, Miller E. The burden of influenza in England by age and clinical risk group: a statistical analysis to inform vaccine policy. J Inf Secur. 2014;68(4):363–371.
    1. Cromer D, van Hoek AJ, Newall AT, Pollard AJ, Jit M. Burden of paediatric respiratory syncytial virus disease and potential effect of different immunisation strategies: a modelling and cost-effectiveness analysis for England. Lancet Public Health. 2017;2(8):e367–e374. doi: 10.1016/S2468-2667(17)30103-2.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren